# GLYCOLYSIS: A Comprehensive and Detailed Guide --- ## 1. INTRODUCTION AND DEFINITION **Glycolysis** (Greek: *glykys* = sweet, *lysis* = splitting/dissolution) is the metabolic pathway in which one molecule of **glucose (C₆H₁₂O₆)** is oxidized and split into two molecules of **pyruvate (C₃H₄O₃)**. It is also known as the **Embden-Meyerhof-Parnas (EMP) Pathway**, named after Gustav Embden, Otto Meyerhof, and Jakub Karol Parnas, who elucidated the pathway in the 1930s-1940s. ### Key Features at a Glance: - **Location:** Cytoplasm (cytosol) of virtually all living cells - **Oxygen requirement:** None — it is an **anaerobic** process (occurs with or without oxygen) - **Substrate:** Glucose (6-carbon sugar) - **End products:** - **Aerobic conditions:** 2 Pyruvate - **Anaerobic conditions:** 2 Lactate (in animals) or 2 Ethanol + 2 CO₂ (in yeast) - **Net yield per glucose:** 2 ATP + 2 NADH (under aerobic conditions) - **Number of reactions:** 10 enzymatic steps - **Universality:** Found in virtually all organisms — prokaryotes and eukaryotes ### Why is Glycolysis Important? 1. It is the **most ancient** metabolic pathway (evolved before oxygen appeared in the atmosphere ~2.4 billion years ago) 2. It is the **central pathway** of carbohydrate metabolism 3. It provides **carbon skeletons** for biosynthesis (amino acids, lipids, etc.) 4. It generates **ATP** rapidly (important in emergencies, e.g., sprinting) 5. It is the **gateway** to the TCA cycle, HMP shunt, and gluconeogenesis 6. Certain tissues depend **entirely** on glycolysis (e.g., RBCs, cornea, lens, renal medulla) --- ## 2. SUBCELLULAR LOCATION All 10 enzymes of glycolysis are present as **soluble proteins in the cytosol**. However, recent evidence shows some glycolytic enzymes can associate with: - **Cytoskeletal elements** (actin filaments) - **Mitochondrial outer membrane** (hexokinase II in muscle and tumor cells — clinically significant) - **Erythrocyte membrane** (band 3 protein association) > **Clinical Correlation — Hexokinase II and Cancer:** > In cancer cells, hexokinase II binds to the **voltage-dependent anion channel (VDAC)** on the mitochondrial outer membrane. This gives the enzyme preferential access to mitochondrially-generated ATP and also **inhibits apoptosis** by preventing cytochrome c release. This is a therapeutic target in oncology. --- ## 3. OVERVIEW OF THE PATHWAY Glycolysis can be divided into **two phases**: ### Phase I: Preparatory (Energy-Investment) Phase - **Steps 1–5** - Glucose is phosphorylated, rearranged, and split into two 3-carbon (triose) fragments - **2 ATP molecules are consumed** (invested) - Also called the **"priming phase"** ### Phase II: Payoff (Energy-Generation) Phase - **Steps 6–10** - The two triose phosphates are oxidized and converted to pyruvate - **4 ATP molecules and 2 NADH** are generated - Also called the **"harvest phase"** ### Net Equation: ``` Glucose + 2 NAD⁺ + 2 ADP + 2 Pᵢ → 2 Pyruvate + 2 NADH + 2 H⁺ + 2 ATP + 2 H₂O ``` --- ## 4. DETAILED STEP-BY-STEP REACTIONS --- ### **STEP 1: Phosphorylation of Glucose to Glucose-6-Phosphate** ``` Glucose + ATP → Glucose-6-Phosphate (G6P) + ADP ``` **Enzyme:** **Hexokinase** (in most tissues) / **Glucokinase** (in liver and pancreatic β-cells) **Type of reaction:** Phosphorylation (phosphotransferase reaction) **Detailed Mechanism:** - The enzyme transfers the **γ-phosphoryl group** from ATP to the **C-6 hydroxyl group** of glucose - Requires **Mg²⁺** (or Mn²⁺) as a cofactor — Mg²⁺ forms a complex with ATP (MgATP²⁻), which is the true substrate - The reaction is essentially **irreversible** (ΔG°' = −16.7 kJ/mol; ΔG in cells ≈ −33.4 kJ/mol) - This is the **first regulatory step** and the **first committed step** of glucose metabolism in general (but not the committed step of glycolysis specifically — that is step 3) **Why phosphorylate glucose?** 1. **Trapping:** Glucose-6-phosphate cannot cross the cell membrane (no transporter for phosphorylated sugars), so glucose is "trapped" inside the cell 2. **Activation:** The phosphoryl group raises the free energy of glucose, making subsequent reactions thermodynamically favorable 3. **Specificity:** Provides a handle for enzyme recognition #### Hexokinase vs. Glucokinase — A Critical Comparison: | Feature | Hexokinase (I, II, III) | Glucokinase (Hexokinase IV) | |---|---|---| | **Tissue distribution** | Most tissues (muscle, brain, RBC, etc.) | Liver, pancreatic β-cells, hypothalamus, gut | | **Km for glucose** | Low (~0.1 mM) — high affinity | High (~10 mM) — low affinity | | **Vmax** | Low | High | | **Substrate specificity** | Broad — acts on glucose, fructose, mannose, galactose | Highly specific for **glucose** | | **Product inhibition** | **Yes** — inhibited by G6P | **No** — not inhibited by G6P | | **Molecular weight** | ~100 kDa (monomer for HK I, II, III) | ~50 kDa (monomer) | | **Isoform** | HK I (brain), HK II (muscle), HK III | HK IV | | **Regulation by insulin** | Not significantly induced | **Induced by insulin** (transcription increased) | | **Sigmoidal/Hyperbolic kinetics** | Hyperbolic (Michaelis-Menten) | **Sigmoidal** (positive cooperativity-like but actually monomeric — kinetic cooperativity via slow conformational change) | | **Glucokinase regulatory protein (GKRP)** | Not applicable | **Yes** — regulated by GKRP in liver (sequesters GK in nucleus when fructose-6-P is high; releases when fructose-1-P or glucose is high) | | **Physiological role** | Captures glucose even at low blood glucose (fed or fasting) | Acts as a **glucose sensor**; phosphorylates glucose only when blood glucose is high (postprandially) | **Glucokinase as a Glucose Sensor:** - In **pancreatic β-cells**, glucokinase determines the rate of glucose metabolism, which controls **insulin secretion** - The Km (~10 mM) is close to the normal blood glucose concentration (~5 mM), so its activity changes proportionally with blood glucose > **Clinical Correlation — MODY-2 (Maturity Onset Diabetes of the Young, Type 2):** > Mutations in the **glucokinase gene (GCK)** cause MODY-2, an autosomal dominant form of diabetes. The mutated glucokinase has a higher Km, so the β-cell requires higher glucose concentrations to trigger insulin secretion. Patients have **mild, stable fasting hyperglycemia** (~5.5–8 mM) from birth. Usually does not require treatment. > **Clinical Correlation — Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI):** > **Activating mutations** in glucokinase (lowering the Km for glucose) cause the β-cells to secrete insulin even at very low blood glucose levels, resulting in **severe neonatal hypoglycemia**. > **Clinical Correlation — Glucokinase Activators (GKAs):** > Pharmaceutical companies have developed **glucokinase activator drugs** for type 2 diabetes therapy. These drugs lower the Km and increase Vmax of glucokinase, enhancing glucose-stimulated insulin secretion and hepatic glucose uptake. Examples: Dorzagliatin (approved in China, 2022). --- ### **STEP 2: Isomerization of Glucose-6-Phosphate to Fructose-6-Phosphate** ``` Glucose-6-Phosphate ⇌ Fructose-6-Phosphate (F6P) ``` **Enzyme:** **Phosphoglucose Isomerase** (PGI) / Glucose-6-phosphate isomerase / Phosphohexose isomerase **Type of reaction:** Isomerization (aldose → ketose conversion) **Detailed Mechanism:** - Converts an **aldose** (glucose-6-phosphate, which has an aldehyde at C-1) to a **ketose** (fructose-6-phosphate, which has a ketone at C-2) - Involves an **enediol intermediate** - The ring opens, the C-1 aldehyde is reduced and C-2 is oxidized, then the ring closes as a furanose - Reaction is **freely reversible** (ΔG°' = +1.7 kJ/mol) - Requires **Mg²⁺** **Why is this step necessary?** - To place the carbonyl group at C-2, which is essential for the subsequent phosphorylation at C-1 (step 3) and eventual symmetric cleavage of the molecule in step 4 > **Clinical Correlation — PGI as a Tumor Marker and Autocrine Motility Factor:** > Phosphoglucose isomerase is identical to: > 1. **Autocrine motility factor (AMF)** — secreted by tumor cells, stimulates cell migration and metastasis > 2. **Neuroleukin** — a neurotrophic factor > 3. **Maturation factor** — mediates differentiation of human myeloid leukemia cells > Elevated serum PGI levels are found in cancers (breast, lung, colorectal) and can serve as a **tumor marker**. > **Clinical Correlation — Hemolytic Anemia (PGI Deficiency):** > PGI deficiency is the **second most common glycolytic enzyme deficiency** causing hereditary non-spherocytic hemolytic anemia (after pyruvate kinase deficiency). RBCs are particularly vulnerable because they depend entirely on glycolysis for ATP. --- ### **STEP 3: Phosphorylation of Fructose-6-Phosphate to Fructose-1,6-Bisphosphate** ``` Fructose-6-Phosphate + ATP → Fructose-1,6-Bisphosphate (F1,6BP) + ADP ``` **Enzyme:** **Phosphofructokinase-1 (PFK-1)** **Type of reaction:** Phosphorylation **This is the most important regulatory step — the RATE-LIMITING STEP and the COMMITTED STEP of glycolysis.** **Detailed Mechanism:** - Transfers the γ-phosphoryl group of ATP to the C-1 hydroxyl group of fructose-6-phosphate - Requires **Mg²⁺** - **Irreversible** (ΔG°' = −14.2 kJ/mol; in cells ΔG ≈ −25.9 kJ/mol) - PFK-1 is a **tetrameric** enzyme (homotetramer in bacteria; in mammals, exists as homotetramers or heterotetramers of L, M, and P subunits) **Why is this the committed step?** - G6P and F6P can enter other pathways (HMP shunt, glycogen synthesis), but once F1,6BP is formed, the molecule is **committed to glycolysis** #### Regulation of PFK-1 (THE MOST REGULATED ENZYME IN GLYCOLYSIS): **Allosteric Activators:** 1. **AMP** (indicates low energy charge) 2. **ADP** (indicates energy depletion) 3. **Fructose-2,6-bisphosphate (F2,6BP)** — **THE MOST POTENT ACTIVATOR** (discussed in detail below) 4. **Inorganic phosphate (Pᵢ)** 5. **NH₄⁺** (in liver — signals amino acid catabolism) 6. **Fructose-6-phosphate** (substrate) 7. **K⁺** **Allosteric Inhibitors:** 1. **ATP** (at the allosteric/regulatory site — NOT the catalytic site; high ATP indicates energy sufficiency) 2. **Citrate** (indicates TCA cycle is saturated; fatty acid synthesis is active) 3. **H⁺ (low pH)** — protects the heart during ischemia by slowing glycolysis and preventing excessive lactate/H⁺ accumulation 4. **Glucagon (via decreased F2,6BP in liver)** 5. **Long-chain fatty acids** 6. **Phosphoenolpyruvate (PEP)** — in some organisms #### The Fructose-2,6-Bisphosphate Story (F2,6BP): **F2,6BP is NOT a glycolytic intermediate**. It is a **regulatory molecule** produced by the **bifunctional enzyme PFK-2/FBPase-2 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase)**. This single polypeptide has **two catalytic activities:** - **PFK-2 (kinase) domain** — makes F2,6BP from F6P + ATP - **FBPase-2 (phosphatase) domain** — hydrolyzes F2,6BP back to F6P + Pᵢ **Regulation in the LIVER (the classic paradigm):** - **Insulin** (fed state) → activates a **protein phosphatase** → **dephosphorylates** the bifunctional enzyme → **PFK-2 is ACTIVE** (kinase active) → F2,6BP levels **increase** → **glycolysis is stimulated** - **Glucagon** (fasting state) → activates **adenylyl cyclase** → cAMP → **PKA (protein kinase A)** → **phosphorylates** the bifunctional enzyme at **Ser32** → **FBPase-2 is ACTIVE** (phosphatase active) → F2,6BP levels **decrease** → glycolysis is **inhibited** and gluconeogenesis is **stimulated** (because F2,6BP also inhibits fructose-1,6-bisphosphatase, the gluconeogenic enzyme) **In heart and skeletal muscle:** - The muscle isoform (PFK-2/FBPase-2) is **activated by phosphorylation** (opposite to the liver!). AMP-activated protein kinase (AMPK) phosphorylates PFK-2 in the heart, increasing F2,6BP and stimulating glycolysis during ischemia. > **Clinical Correlation — Warburg Effect and PFK-1 in Cancer:** > Cancer cells exhibit the **Warburg Effect** — high rates of aerobic glycolysis (glycolysis even in the presence of oxygen). PFK-1 activity is markedly upregulated due to: > 1. **Overexpression of PFK-2 (PFKFB3 isoform)** → high F2,6BP levels > 2. **HIF-1α** (hypoxia-inducible factor) upregulates glycolytic enzymes including PFK-1 > 3. **Oncogenes** (Ras, Myc, Akt) stimulate glycolysis > **PFKFB3 inhibitors** are being explored as anticancer drugs. > **Clinical Correlation — PFK-1 Deficiency (Tarui Disease / Glycogen Storage Disease Type VII):** > Deficiency of the **muscle (M) subunit** of PFK-1 causes **Tarui disease**. Features: > - Exercise intolerance, myopathy, cramps > - **Hemolytic anemia** (RBCs have partial PFK activity since they express both M and L subunits) > - **Hyperuricemia** (excess purine degradation from accelerated nucleotide catabolism) > - **NO improvement with glucose infusion** (unlike McArdle disease) — in fact, glucose may worsen symptoms ("out-of-wind" phenomenon) because glucose lowers free fatty acid availability **Note on nomenclature:** - **Fructose-1,6-bisphosphate** has two phosphates on different carbons (C1 and C6) — hence "BIS" - **Fructose-2,6-bisphosphate** similarly has phosphates on C2 and C6 - This is different from "di-phosphate" which would imply two phosphates on the same carbon --- ### **STEP 4: Cleavage of Fructose-1,6-Bisphosphate into Two Triose Phosphates** ``` Fructose-1,6-Bisphosphate ⇌ Dihydroxyacetone Phosphate (DHAP) + Glyceraldehyde-3-Phosphate (G3P) ``` **Enzyme:** **Aldolase** (Fructose bisphosphate aldolase) **Type of reaction:** Aldol cleavage (retro-aldol condensation) **Detailed Mechanism:** - The C3–C4 bond is cleaved via a retro-aldol reaction - **Class I Aldolase** (animals, plants): Forms a **Schiff base** (covalent intermediate) between the substrate's C-2 carbonyl and a **lysine residue** (Lys-229) in the active site. The Schiff base acts as an electron sink. - **Class II Aldolase** (bacteria, fungi): Uses a **Zn²⁺** metal ion as a Lewis acid to stabilize the carbanion intermediate (no Schiff base) - Reaction is **thermodynamically unfavorable** in isolation (ΔG°' = +23.8 kJ/mol) but is pulled forward because the products are rapidly removed by subsequent reactions (Le Chatelier's principle) - Products: **DHAP** (a ketose) and **G3P** (an aldose) **Three isoforms of aldolase in humans:** - **Aldolase A** — muscle, brain, RBCs (most tissues) - **Aldolase B** — liver, kidney, small intestine - **Aldolase C** — brain, nervous tissue > **Clinical Correlation — Hereditary Fructose Intolerance (HFI):** > **Aldolase B deficiency** causes HFI. This is NOT directly a glycolytic defect, but aldolase B also cleaves **fructose-1-phosphate** (from dietary fructose metabolism). > - Fructose-1-phosphate accumulates in the liver → **traps inorganic phosphate** → depletes ATP → inhibits glycogenolysis and gluconeogenesis > - Symptoms: Severe **hypoglycemia**, **vomiting**, **hepatomegaly**, **jaundice**, **renal tubular dysfunction** after ingesting fructose or sucrose > - **Autosomal recessive** > - Treatment: **Strict avoidance** of fructose, sucrose, and sorbitol > - **Differentiate from:** Essential fructosuria (fructokinase deficiency — benign, asymptomatic) > **Clinical Correlation — Aldolase as a Diagnostic Marker:** > Serum aldolase A levels are elevated in **muscular dystrophies** (Duchenne), **hepatitis**, **myocardial infarction**, and certain **cancers**. It has been largely replaced by more specific markers (CK-MB, troponins) but is still occasionally used in evaluating myopathies. --- ### **STEP 5: Interconversion of Triose Phosphates** ``` Dihydroxyacetone Phosphate (DHAP) ⇌ Glyceraldehyde-3-Phosphate (G3P) ``` **Enzyme:** **Triose Phosphate Isomerase (TPI / TIM)** **Type of reaction:** Isomerization (ketose ⇌ aldose) **Detailed Mechanism:** - Converts DHAP (a dead-end product for glycolysis) to G3P (the substrate for step 6) - Only **G3P** continues in glycolysis; therefore BOTH trioses are effectively channeled through the remaining steps - Proceeds via an **enediol intermediate** (similar to step 2) - **Near-perfect enzyme** — catalytically perfect, diffusion-limited enzyme (kcat/Km ≈ 10⁸–10⁹ M⁻¹s⁻¹) — the rate is limited only by how fast substrate can diffuse into the active site - Equilibrium strongly favors DHAP (96% DHAP : 4% G3P at equilibrium), but is pulled toward G3P because G3P is continuously consumed in step 6 - A **key catalytic residue** is **Glu-165**, which acts as a general base, and a **flexible loop (loop 6)** closes over the active site during catalysis to prevent loss of the enediol intermediate (which could decompose to toxic **methylglyoxal**) > **Clinical Correlation — Triose Phosphate Isomerase Deficiency:** > TPI deficiency is the **most severe glycolytic enzymopathy** and is **autosomal recessive**. > - Causes **chronic hemolytic anemia**, **progressive neuromuscular dysfunction** (spasticity, dystonia), **cardiomyopathy**, and **increased susceptibility to infection** > - Most patients die in **early childhood** (usually before age 5) > - Accumulation of DHAP leads to formation of **methylglyoxal**, a highly reactive dicarbonyl compound that causes **protein glycation** and oxidative damage > - Most common mutation: **Glu104Asp** (a conservative change, but devastating functionally) > **Clinical Correlation — Methylglyoxal and Diabetes:** > Even in normal metabolism, small amounts of methylglyoxal are produced from DHAP and G3P. In **diabetes mellitus**, increased glycolysis and triose phosphate accumulation lead to **elevated methylglyoxal**, contributing to: > - **Advanced glycation end products (AGEs)** > - **Diabetic complications** (neuropathy, nephropathy, retinopathy) > - The **glyoxalase system** (glyoxalase I + II, using glutathione) detoxifies methylglyoxal to D-lactate **After Step 5, from the standpoint of one glucose molecule, all subsequent reactions occur TWICE (once for each G3P molecule).** --- ## ═══ PHASE II: THE PAYOFF PHASE (Steps 6–10) ═══ From this point, remember: **Everything happens ×2 per glucose molecule.** --- ### **STEP 6: Oxidation and Phosphorylation of Glyceraldehyde-3-Phosphate** ``` G3P + NAD⁺ + Pᵢ → 1,3-Bisphosphoglycerate (1,3-BPG) + NADH + H⁺ ``` **Enzyme:** **Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH / G3PDH)** **Type of reaction:** Oxidation + Phosphorylation (coupled oxidative phosphorylation — NOT mitochondrial oxidative phosphorylation, but **substrate-level** coupling) **This is the ONLY oxidation step in glycolysis.** **Detailed Mechanism (multi-step):** 1. **Covalent catalysis:** The aldehyde group of G3P reacts with the **sulfhydryl group (-SH)** of **Cys-149** in the active site → forms a **hemithioacetal** 2. **Oxidation:** The hemithioacetal is oxidized by **NAD⁺** (bound in the active site) to a **thioester** (high-energy acyl-enzyme intermediate) → NAD⁺ is reduced to **NADH** 3. **Phosphorolysis:** Inorganic phosphate (Pᵢ) attacks the thioester bond → releases the **acyl phosphate** product (1,3-BPG) and regenerates the free enzyme 4. **NADH exchange:** The NADH must leave the active site and be replaced by a new NAD⁺ for the next catalytic cycle **Key Points:** - The reaction conserves the energy of oxidation in the **high-energy acyl phosphate bond** of 1,3-BPG (mixed anhydride of a carboxylic acid and phosphoric acid) - The energy of the thioester intermediate (which is high-energy) is used to drive the formation of 1,3-BPG - **NADH** produced here must be **reoxidized** back to NAD⁺ for glycolysis to continue (see section on NADH shuttles and anaerobic fate) - The reaction is **reversible** (ΔG°' = +6.3 kJ/mol) but driven forward by removal of products **Why is this step so important?** - It couples an energetically favorable oxidation to the formation of a **high-energy phosphate compound** (1,3-BPG) - Without this coupling, the energy of oxidation would be lost as heat - The high-energy phosphate of 1,3-BPG will be used in step 7 to generate ATP by **substrate-level phosphorylation** > **Clinical Correlation — GAPDH as a Multifunctional Protein:** > GAPDH has emerged as a remarkably multifunctional protein beyond glycolysis: > 1. **DNA repair** — involved in base excision repair > 2. **Apoptosis** — nuclear translocation of GAPDH promotes cell death (relevant in neurodegenerative diseases) > 3. **Membrane fusion** and **vesicular transport** > 4. **Gene transcription** regulation > 5. **Viral replication** — exploited by hepatitis C and other viruses > > In **Alzheimer's and Parkinson's disease**, GAPDH aggregation contributes to neuronal death. The drug **Deprenyl/Selegiline** (MAO-B inhibitor used in Parkinson's) may partly work by preventing GAPDH nuclear translocation. > **Clinical Correlation — Arsenate Poisoning:** > **Arsenate (AsO₄³⁻)** structurally resembles **phosphate (PO₄³⁻)** and competes with Pᵢ in step 6. > - Arsenate substitutes for Pᵢ → forms **1-arseno-3-phosphoglycerate** instead of 1,3-BPG > - This arsenate ester is **unstable** and spontaneously hydrolyzes (arsenolysis) → produces **3-phosphoglycerate** directly (bypassing step 7) > - **Result:** The ATP that would have been generated in step 7 is **LOST** > - Net ATP yield drops to **ZERO** (instead of +2) > - This is called **"arsenate uncoupling"** of glycolysis — oxidation occurs but without coupled ATP production > - Arsenate also inhibits pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (contains lipoamide) → further metabolic devastation > **Clinical Correlation — Iodoacetate Poisoning:** > **Iodoacetate** (ICH₂COO⁻) is an **irreversible inhibitor** of GAPDH. It alkylates the essential **Cys-149** in the active site, permanently inactivating the enzyme. This completely blocks glycolysis. Used experimentally to study glycolysis. --- ### **STEP 7: Transfer of Phosphoryl Group from 1,3-BPG to ADP — First Substrate-Level Phosphorylation** ``` 1,3-Bisphosphoglycerate + ADP → 3-Phosphoglycerate (3-PG) + ATP ``` **Enzyme:** **Phosphoglycerate Kinase (PGK)** **Type of reaction:** Substrate-level phosphorylation **Detailed Mechanism:** - The **high-energy acyl phosphate** at C-1 of 1,3-BPG is transferred to ADP → forms ATP - Requires **Mg²⁺** - This is the first ATP-generating step in glycolysis - The reaction is **reversible** (ΔG°' = −18.5 kJ/mol, but the ΔG in cells is close to zero because of concentration effects) - Named "kinase" because the reaction is named in the **reverse direction** (3-PG + ATP → 1,3-BPG + ADP) by convention **Substrate-Level Phosphorylation:** - ATP is formed directly by transfer of a phosphoryl group from a substrate to ADP - Does NOT involve the electron transport chain or oxygen - In glycolysis, there are **two** substrate-level phosphorylation steps: step 7 and step 10 **Energy accounting at this point (per glucose):** - 2 ATP invested (steps 1 and 3) - 2 ATP produced here (2 × step 7) - **Net = 0 ATP** so far (break-even point) > **Clinical Correlation — 2,3-Bisphosphoglycerate (2,3-BPG) and the Rapoport-Luebering Shunt:** > > In **erythrocytes**, 1,3-BPG can be diverted from glycolysis into the **Rapoport-Luebering Pathway (Bisphosphoglycerate Shunt)**: > > ``` > 1,3-BPG → (BPG Mutase/Synthase) → 2,3-BPG → (2,3-BPG Phosphatase) → 3-PG > ``` > > **2,3-BPG** is present at ~5 mM in RBCs (equimolar with hemoglobin) and is the **most important allosteric regulator of hemoglobin oxygen affinity**: > - 2,3-BPG binds to the **central cavity** of deoxyhemoglobin (between β-subunits), **stabilizing the T (tense) state** > - This **decreases oxygen affinity** → **shifts the oxygen-hemoglobin dissociation curve to the RIGHT** → promotes **oxygen release** to tissues > > **Clinical significance of 2,3-BPG:** > - **Increased 2,3-BPG:** High altitude adaptation, chronic anemia, chronic hypoxia, thyrotoxicosis → facilitates oxygen delivery > - **Decreased 2,3-BPG:** Stored blood in blood banks (2,3-BPG depletes within 1-2 weeks) → left shift → poor oxygen delivery; this is why transfused blood initially delivers oxygen poorly > - **Hexokinase deficiency** in RBCs → decreased glycolytic intermediates → decreased 2,3-BPG → left shift → polycythemia (compensatory) > - **Pyruvate kinase deficiency** in RBCs → upstream intermediates accumulate → increased 2,3-BPG → right shift → improved oxygen delivery (partially compensates for anemia) > - **Fetal hemoglobin (HbF)** has **γ-subunits** instead of β-subunits → 2,3-BPG binds less tightly → HbF has higher oxygen affinity → facilitates oxygen transfer from mother to fetus > > **Note:** The Rapoport-Luebering shunt **bypasses step 7**, so the ATP that would have been generated is **lost**. This is the "price" RBCs pay for the 2,3-BPG needed to regulate oxygen delivery. > **Clinical Correlation — Phosphoglycerate Kinase Deficiency:** > PGK deficiency is an **X-linked** disorder (the PGK1 gene is on the X chromosome — one of the few X-linked glycolytic enzyme deficiencies). > - Causes **hemolytic anemia**, **myopathy**, and **intellectual disability/neurological dysfunction** > - Variable severity depending on the specific mutation --- ### **STEP 8: Isomerization of 3-Phosphoglycerate to 2-Phosphoglycerate** ``` 3-Phosphoglycerate ⇌ 2-Phosphoglycerate (2-PG) ``` **Enzyme:** **Phosphoglycerate Mutase (PGM)** **Type of reaction:** Intramolecular phosphoryl transfer (mutase — shifts a functional group within the same molecule) **Detailed Mechanism:** - The phosphoryl group moves from C-3 to C-2 - In most mammals, this involves a **2,3-bisphosphoglycerate (2,3-BPG) intermediate** and an active-site **histidine** residue (His-11 in the human enzyme): 1. The phospho-enzyme (His-P) transfers its phosphate to C-2 of 3-PG → forms 2,3-BPG 2. The enzyme then removes the phosphate from C-3 of 2,3-BPG → regenerates the phospho-enzyme + 2-PG - Requires **catalytic amounts of 2,3-BPG** to initially phosphorylate the histidine and prime the enzyme - **Freely reversible** (ΔG°' = +4.4 kJ/mol) - Requires **Mg²⁺** **Why is this step necessary?** - Moving the phosphate from C-3 to C-2 is essential for the next step (step 9), where dehydration creates the high-energy phosphoenolpyruvate. The phosphate must be on C-2 for this chemistry to work. > **Clinical Correlation — Phosphoglycerate Mutase Deficiency:** > Very rare. Causes **exercise intolerance**, **myopathy**, and **exercise-induced rhabdomyolysis with myoglobinuria**. Muscle biopsy shows glycogen accumulation. --- ### **STEP 9: Dehydration of 2-Phosphoglycerate to Phosphoenolpyruvate** ``` 2-Phosphoglycerate → Phosphoenolpyruvate (PEP) + H₂O ``` **Enzyme:** **Enolase** (Phosphopyruvate hydratase) **Type of reaction:** Dehydration (elimination of water) **Detailed Mechanism:** - Removes water (H from C-2, OH from C-3) to create a **double bond** between C-2 and C-3 - Creates **PEP**, which has the **highest phosphoryl transfer potential** of any common biological molecule (ΔG°' of hydrolysis = −61.9 kJ/mol, compared to −30.5 kJ/mol for ATP) - **Near-equilibrium** (ΔG°' = +7.5 kJ/mol for dehydration, but driven forward) - Requires **Mg²⁺** (two Mg²⁺ ions per active site) - Enolase exists as a **dimer** with three tissue-specific isoforms: - **αα** — ubiquitous (liver, kidney) - **ββ** — muscle-specific - **γγ** — neuron-specific (NSE — neuron-specific enolase) **Why is PEP so high-energy?** - The phosphoryl group "traps" the molecule in the unstable enol form of pyruvate - Upon dephosphorylation (step 10), the enol spontaneously tautomerizes to the much more stable **keto form** of pyruvate - The large negative ΔG of PEP hydrolysis comes mainly from this **keto-enol tautomerization** plus increased resonance stabilization of the products > **Clinical Correlation — Fluoride Inhibition of Enolase:** > **Fluoride (F⁻)** inhibits enolase by forming a complex with **Mg²⁺ and phosphate** → **magnesium fluorophosphate** complex that blocks the active site. > - This is why **sodium fluoride (NaF)** is added to blood collection tubes for **glucose estimation** — it inhibits glycolysis in vitro, preventing glucose consumption by RBCs and WBCs, ensuring accurate blood glucose measurement > - Fluoride in **toothpaste** also inhibits bacterial enolase → reduces bacterial glycolysis → decreases lactic acid production → **prevents dental caries** > - Fluoride also inhibits the enzyme proton-translocating ATPase in bacteria > **Clinical Correlation — Neuron-Specific Enolase (NSE) as a Tumor Marker:** > **NSE (γγ enolase)** is a tumor marker for: > 1. **Small cell lung carcinoma (SCLC)** — most important clinical use > 2. **Neuroblastoma** > 3. **Melanoma** > 4. **Neuroendocrine tumors** (carcinoid, pheochromocytoma) > 5. **Traumatic brain injury** — elevated serum NSE indicates neuronal damage > 6. **Creutzfeldt-Jakob disease** — elevated CSF NSE --- ### **STEP 10: Transfer of Phosphoryl Group from PEP to ADP — Second Substrate-Level Phosphorylation** ``` Phosphoenolpyruvate + ADP → Pyruvate + ATP ``` **Enzyme:** **Pyruvate Kinase (PK)** **Type of reaction:** Substrate-level phosphorylation **This is the THIRD IRREVERSIBLE reaction and the SECOND REGULATORY POINT of glycolysis.** **Detailed Mechanism:** - The phosphoryl group of PEP is transferred to ADP → ATP - Requires **Mg²⁺** (and **K⁺** as essential activators) - The initial product is **enol-pyruvate**, which spontaneously undergoes **tautomerization** to the more stable **keto-pyruvate** - **Irreversible** (ΔG°' = −31.4 kJ/mol; ΔG in cells ≈ −23 kJ/mol) - The large negative ΔG is driven by the tautomerization of enolpyruvate to ketopyruvate **Isoforms of Pyruvate Kinase:** | Isoform | Tissue | Key features | |---|---|---| | **PK-L** | Liver | Regulated by phosphorylation (glucagon/insulin), allosteric regulation | | **PK-R** | RBCs (erythrocytes) | Related to L form, alternative splicing of same gene (PKLR) | | **PK-M1** | Muscle, heart, brain | Constitutively active, not allosterically regulated by F1,6BP | | **PK-M2** | Fetal tissues, proliferating cells, **CANCER CELLS** | Exists as less active dimer; regulated form; important in Warburg effect | #### Regulation of Pyruvate Kinase: **A. Allosteric Regulation:** *Activators:* - **Fructose-1,6-bisphosphate (F1,6BP)** — **feedforward activator** (product of step 3 activates step 10 — ensures coordinated flux through glycolysis). This is an example of **feedforward stimulation**. *Inhibitors:* - **ATP** (product inhibition — high energy charge) - **Alanine** (signals amino acid abundance; alanine is transaminated to pyruvate, so if pyruvate-derived amino acids are abundant, there's no need to produce more pyruvate) - **Acetyl-CoA** (signals adequacy of fuel for TCA cycle) - **Long-chain fatty acids** - **Phenylalanine** (inhibits PK-L) **B. Covalent Modification (Liver PK-L only):** - **Glucagon** (fasting) → cAMP → PKA → **phosphorylates** PK-L → **INACTIVATION** (reduces Vmax, increases Km for PEP) - This prevents the liver from consuming pyruvate/PEP during fasting when gluconeogenesis is needed - **Insulin** (fed state) → activates protein phosphatase → dephosphorylates PK-L → **ACTIVATION** - Note: Muscle PK (M1) is NOT regulated by phosphorylation (muscle needs to maintain glycolysis regardless of fasting state) **C. Transcriptional Regulation:** - **Insulin** and **high carbohydrate diet** → increase transcription of PK-L gene - **Glucagon** and **fasting** → decrease PK-L gene transcription > **Clinical Correlation — Pyruvate Kinase Deficiency:** > PK deficiency (specifically **PK-R** isoform — the erythrocyte form) is the **most common** glycolytic enzyme deficiency causing **hereditary non-spherocytic hemolytic anemia**. > - **Autosomal recessive** (PKLR gene mutations) > - **Pathophysiology:** RBCs depend entirely on glycolysis for ATP. Reduced PK activity → decreased ATP → impaired Na⁺/K⁺-ATPase → loss of RBC membrane integrity → **hemolysis** > - **Paradoxically**, these patients tolerate anemia relatively well because: > - Upstream glycolytic intermediates accumulate → **increased 2,3-BPG** → right shift of O₂ dissociation curve → better oxygen delivery to tissues > - This is a compensatory mechanism > - **Blood smear:** Echinocytes (spiculated cells/"burr cells"), NOT spherocytes (hence "non-spherocytic") > - **Treatment:** Transfusions in severe cases; splenectomy may help; iron chelation if iron overload develops; **Mitapivat** (AG-348) — a novel **PK activator drug** — has been FDA-approved (2022) for PK deficiency in adults > - RBCs lack mitochondria, so they cannot compensate by oxidative phosphorylation > **Clinical Correlation — PKM2 and Cancer:** > **PKM2** is the embryonic/cancer isoform of pyruvate kinase. In cancer cells: > - PKM2 exists primarily as a **less active dimer** (rather than the fully active tetramer) > - The **low PK activity** causes upstream glycolytic intermediates to accumulate → these are diverted into **biosynthetic pathways** (pentose phosphate pathway for nucleotide synthesis, serine synthesis pathway, lipid synthesis) → supports rapid cell proliferation > - PKM2 can also **translocate to the nucleus** and function as a **transcriptional coactivator** (works with HIF-1α, β-catenin) to promote tumor growth > - **PKM2 activators** (e.g., TEPP-46, DASA-58) force PKM2 into the tetramer form → restore high PK activity → reduce diversion of intermediates → potential anticancer therapy > - **PKM2 is a potential diagnostic biomarker** detectable in blood and stool for colorectal and other cancers --- ## 5. SUMMARY OF THE 10 REACTIONS | Step | Substrate | Product | Enzyme | Type | Reversible? | ATP Change | |---|---|---|---|---|---|---| | 1 | Glucose | G6P | Hexokinase/Glucokinase | Phosphorylation | **Irreversible** | −1 ATP | | 2 | G6P | F6P | Phosphoglucose isomerase | Isomerization | Reversible | — | | 3 | F6P | F1,6BP | **PFK-1** | Phosphorylation | **Irreversible** | −1 ATP | | 4 | F1,6BP | DHAP + G3P | Aldolase | Aldol cleavage | Reversible | — | | 5 | DHAP | G3P | Triose phosphate isomerase | Isomerization | Reversible | — | | 6 | G3P | 1,3-BPG | GAPDH | Oxidation + Phosphorylation | Reversible | +NADH | | 7 | 1,3-BPG | 3-PG | Phosphoglycerate kinase | Substrate-level phosphorylation | Reversible | **+1 ATP (×2)** | | 8 | 3-PG | 2-PG | Phosphoglycerate mutase | Intramolecular transfer | Reversible | — | | 9 | 2-PG | PEP | Enolase | Dehydration | Reversible | — | | 10 | PEP | Pyruvate | **Pyruvate kinase** | Substrate-level phosphorylation | **Irreversible** | **+1 ATP (×2)** | --- ## 6. ENERGY YIELD OF GLYCOLYSIS ### Direct ATP Yield (Substrate-Level Phosphorylation): - ATP consumed: **2** (steps 1 and 3) - ATP produced: **4** (2 × step 7 + 2 × step 10) - **Net ATP by substrate-level phosphorylation = 2 ATP per glucose** ### NADH Yield: - **2 NADH** are produced (2 × step 6) - The fate of these NADH determines additional ATP production: #### Under AEROBIC conditions: NADH must be reoxidized by transferring electrons to the electron transport chain (ETC) in mitochondria. But NADH cannot cross the inner mitochondrial membrane, so **shuttle systems** are used: **1. Malate-Aspartate Shuttle (heart, liver, kidney):** - Cytoplasmic NADH → oxaloacetate reduced to malate → malate enters mitochondria → reoxidized to oxaloacetate → produces mitochondrial NADH → enters ETC at **Complex I** → yields **~2.5 ATP per NADH** - Net from 2 NADH = **5 ATP** **2. Glycerol-3-Phosphate Shuttle (brain, skeletal muscle):** - Cytoplasmic NADH → DHAP reduced to glycerol-3-phosphate (cytoplasmic glycerol-3-phosphate dehydrogenase, NAD⁺-linked) → glycerol-3-phosphate reoxidized by mitochondrial glycerol-3-phosphate dehydrogenase (FAD-linked, on outer surface of inner mitochondrial membrane) → FADH₂ → enters ETC at **Complex II level (via CoQ)** → yields **~1.5 ATP per NADH** - Net from 2 NADH = **3 ATP** ### Total ATP Yield per Glucose (Aerobic Glycolysis): | Component | ATP | |---|---| | Substrate-level phosphorylation | +2 | | 2 NADH via malate-aspartate shuttle | +5 | | **TOTAL (liver, heart)** | **7 ATP** | | OR | | | 2 NADH via glycerol-3-phosphate shuttle | +3 | | **TOTAL (brain, muscle)** | **5 ATP** | *(Complete glucose oxidation through glycolysis + PDH + TCA + ETC yields ~30-32 ATP total)* ### Under ANAEROBIC conditions: - No ETC available → NADH cannot be reoxidized via shuttles → must be reoxidized in the cytoplasm itself - **Net ATP = 2 per glucose** (only substrate-level phosphorylation) --- ## 7. FATE OF PYRUVATE The pyruvate produced by glycolysis has several possible fates depending on the conditions and tissue: ### A. Aerobic Conditions (Most Tissues): ``` Pyruvate + CoA + NAD⁺ → Acetyl-CoA + CO₂ + NADH ``` - **Enzyme:** Pyruvate Dehydrogenase Complex (PDC) - Acetyl-CoA enters the **TCA cycle** for complete oxidation - **Location:** Mitochondrial matrix ### B. Anaerobic Conditions (Muscle, RBCs, Certain Tissues): ``` Pyruvate + NADH + H⁺ → Lactate + NAD⁺ ``` - **Enzyme:** **Lactate Dehydrogenase (LDH)** - This regenerates **NAD⁺** so glycolysis can continue - Critical for tissues without mitochondria (RBCs) or under hypoxia (exercising muscle) ### C. Anaerobic Conditions (Yeast — Alcoholic Fermentation): ``` Pyruvate → Acetaldehyde + CO₂ (pyruvate decarboxylase, requires TPP) Acetaldehyde + NADH + H⁺ → Ethanol + NAD⁺ (alcohol dehydrogenase) ``` - This is the basis of **brewing and winemaking** ### D. Transamination (Liver, Muscle): ``` Pyruvate + Glutamate ⇌ Alanine + α-Ketoglutarate ``` - **Enzyme:** Alanine aminotransferase (ALT/GPT) - Important in the **glucose-alanine cycle** between muscle and liver ### E. Carboxylation (Liver — Gluconeogenesis): ``` Pyruvate + CO₂ + ATP → Oxaloacetate + ADP + Pᵢ ``` - **Enzyme:** Pyruvate carboxylase (requires biotin) - First step of gluconeogenesis --- ## 8. LACTATE DEHYDROGENASE (LDH) — DETAILED DISCUSSION **Reaction:** ``` Pyruvate + NADH + H⁺ ⇌ Lactate + NAD⁺ ``` - LDH is a **tetramer** of two types of subunits: **H (heart)** and **M (muscle)** - Five isoforms (isozymes): | Isoform | Composition | Predominant tissue | Properties | |---|---|---|---| | LDH-1 | H₄ | Heart, RBCs | High affinity for lactate; inhibited by high pyruvate → favors **lactate → pyruvate** (oxidation) | | LDH-2 | H₃M₁ | RBCs, heart | | | LDH-3 | H₂M₂ | Brain, kidney, lung | | | LDH-4 | H₁M₃ | Liver, skeletal muscle | | | LDH-5 | M₄ | Skeletal muscle, liver | High affinity for pyruvate; not inhibited by high pyruvate → favors **pyruvate → lactate** (reduction) | > **Clinical Correlation — LDH Isoenzymes as Diagnostic Markers:** > > **Myocardial Infarction (MI):** > - Historically, **LDH-1 > LDH-2** ("flipped LDH" pattern) was used as a late marker of MI (rises 12-24 hrs, peaks 2-3 days, normalizes 7-10 days) > - Now largely replaced by **Troponins (TnI, TnT)** and **CK-MB** > - Normal serum: LDH-2 > LDH-1. The "flip" (LDH-1 > LDH-2) also occurs in intravascular hemolysis, megaloblastic anemia, and renal infarction > > **Liver Disease:** Elevated **LDH-5** > > **Megaloblastic Anemia:** Markedly elevated total LDH (due to intramedullary hemolysis and ineffective erythropoiesis). LDH-1 and LDH-2 elevated. > > **Cancer:** LDH is a general tumor marker; elevated in many malignancies (lymphoma, seminoma/testicular germ cell tumors, leukemia). Used as a prognostic marker. > > **Hemolysis:** Elevated LDH (mostly LDH-1, LDH-2) --- ## 9. THE CORI CYCLE (LACTIC ACID CYCLE) During vigorous exercise, skeletal muscle produces **lactate** (from anaerobic glycolysis). This lactate: 1. Is released into the **blood** 2. Transported to the **liver** 3. Converted back to **glucose** by **gluconeogenesis** in the liver 4. Glucose is released into blood → returns to muscle This is the **Cori Cycle** (described by Carl and Gerty Cori, Nobel Prize 1947). **Energy cost:** - Glycolysis in muscle: produces 2 ATP (per glucose → 2 lactate) - Gluconeogenesis in liver: costs 6 ATP (per 2 lactate → glucose) - **Net cost to the body: 4 ATP per cycle** — this energy cost is borne by the liver (using ATP from fatty acid oxidation) > **Clinical Correlation — Lactic Acidosis:** > **Lactic acidosis** occurs when lactate production exceeds hepatic clearance: > > **Type A (Hypoperfusion/Hypoxia-related — most common):** > - Shock (cardiogenic, septic, hypovolemic) > - Severe heart failure > - Severe anemia > - Carbon monoxide poisoning > - Respiratory failure > > **Type B (Non-hypoxia related):** > - **B1 — Associated with disease:** Liver failure (impaired lactate clearance/gluconeogenesis), diabetic ketoacidosis, malignancy (Warburg effect), thiamine deficiency, sepsis > - **B2 — Drug/toxin-induced:** > - **Metformin** (inhibits mitochondrial Complex I → impairs oxidative metabolism → increases lactate) — especially in renal failure > - **Antiretroviral drugs** (NRTIs — e.g., zidovudine, stavudine — inhibit mitochondrial DNA polymerase γ → mitochondrial dysfunction) > - **Cyanide/carbon monoxide poisoning** (inhibit Complex IV) > - **Ethanol** (increases NADH/NAD⁺ ratio → pushes pyruvate → lactate) > - **Salicylate** poisoning (uncouples oxidative phosphorylation) > - Propofol (propofol infusion syndrome) > - Linezolid (inhibits mitochondrial protein synthesis) > - **B3 — Inborn errors of metabolism:** > - Pyruvate dehydrogenase deficiency > - Mitochondrial respiratory chain defects (MELAS — mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) > - Pyruvate carboxylase deficiency > - Glucose-6-phosphatase deficiency (GSD I — Von Gierke disease) > - Fructose-1,6-bisphosphatase deficiency > > **Diagnosis:** Arterial blood lactate > **4 mmol/L** (or > 2 mmol/L with pH < 7.35 = lactic acidosis) > > **Treatment:** Treat underlying cause; optimize oxygen delivery; correct hemodynamics; rarely sodium bicarbonate (controversial — may worsen intracellular acidosis) --- ## 10. GLUCOSE-ALANINE CYCLE Similar to the Cori cycle, but involves **alanine** instead of lactate: 1. In **muscle:** Pyruvate is transaminated with glutamate → **alanine** + α-ketoglutarate (enzyme: ALT) 2. Alanine is transported to the **liver** 3. In liver: Alanine is transaminated back to **pyruvate** → used for **gluconeogenesis** → glucose released to blood → returns to muscle 4. The amino group is converted to **urea** in the liver **Function:** Transports amino groups (from muscle protein breakdown) to the liver for urea synthesis, while simultaneously recycling carbon skeletons for glucose production. --- ## 11. FATE OF CYTOPLASMIC NADH — SHUTTLE SYSTEMS (DETAILED) ### Malate-Aspartate Shuttle (Liver, Heart, Kidney): 1. **Cytoplasm:** Oxaloacetate + NADH → **Malate** + NAD⁺ (cytoplasmic malate dehydrogenase) 2. **Transport:** Malate enters mitochondria via the **malate-α-ketoglutarate antiporter** 3. **Mitochondria:** Malate + NAD⁺ → **Oxaloacetate** + NADH (mitochondrial malate dehydrogenase) 4. Mitochondrial oxaloacetate cannot cross membrane → transaminated to **aspartate** (using glutamate → α-ketoglutarate) 5. Aspartate exits mitochondria via the **glutamate-aspartate antiporter** 6. In cytoplasm: Aspartate → Oxaloacetate (via transamination) — completing the cycle **Result:** NADH is effectively transferred from cytoplasm to mitochondria → **2.5 ATP per NADH** ### Glycerol-3-Phosphate Shuttle (Brain, Skeletal Muscle): 1. **Cytoplasm:** DHAP + NADH → **Glycerol-3-phosphate** + NAD⁺ (cytoplasmic glycerol-3-phosphate dehydrogenase, NAD⁺-linked) 2. **Mitochondrial inner membrane:** Glycerol-3-phosphate → DHAP + **FADH₂** (mitochondrial glycerol-3-phosphate dehydrogenase, FAD-linked — on outer face of inner membrane) 3. FADH₂ transfers electrons to **CoQ** (ubiquinone) in ETC → bypasses Complex I **Result:** Electrons enter at CoQ level → only **1.5 ATP per NADH** (lost one proton-pumping step) --- ## 12. ENTRY OF OTHER SUGARS INTO GLYCOLYSIS ### A. Fructose: **In Liver (main pathway):** 1. Fructose → **Fructose-1-phosphate** (Fructokinase) 2. Fructose-1-phosphate → **DHAP + Glyceraldehyde** (Aldolase B) 3. Glyceraldehyde → **Glyceraldehyde-3-phosphate** (Triose kinase, using ATP) 4. DHAP → enters glycolysis at step 5 5. G3P → enters glycolysis at step 6 **Important:** Fructose enters glycolysis **BELOW PFK-1**, bypassing the major regulatory step → fructose is metabolized **faster and without regulation** → this contributes to its lipogenic (fat-forming) potential **In Muscle/Adipose/Kidney:** - Fructose → **Fructose-6-phosphate** (Hexokinase) → enters glycolysis at step 3 - Minor pathway (hexokinase has low affinity for fructose) > **Clinical Correlation — Essential Fructosuria:** > **Fructokinase** deficiency → fructose is not phosphorylated → fructose appears in blood and urine > - **Benign, asymptomatic** condition > - Autosomal recessive > - Incidental finding (positive Benedict's test for reducing sugars) > - NO treatment needed > **Clinical Correlation — Metabolic Effects of Excess Fructose Consumption:** > High fructose intake (from high-fructose corn syrup, sucrose, fruit juices): > 1. Bypasses PFK-1 regulation → unrestricted glycolytic flux → excess **acetyl-CoA** → **increased lipogenesis** → fatty liver (NAFLD), dyslipidemia (↑ VLDL, ↑ triglycerides) > 2. Rapid ATP consumption by fructokinase → AMP accumulation → increased **uric acid** production (AMP → IMP → hypoxanthine → xanthine → uric acid) → **hyperuricemia and gout** > 3. Contributes to **insulin resistance**, **metabolic syndrome**, and **obesity** > 4. Fructose does not stimulate insulin or leptin secretion → no satiety signal → promotes overeating ### B. Galactose (Leloir Pathway): 1. Galactose → **Galactose-1-phosphate** (Galactokinase) 2. Galactose-1-phosphate + **UDP-glucose** → **UDP-galactose** + **Glucose-1-phosphate** (Galactose-1-phosphate uridylyltransferase — GALT) 3. UDP-galactose → **UDP-glucose** (UDP-galactose-4-epimerase) 4. Glucose-1-phosphate → **Glucose-6-phosphate** (Phosphoglucomutase) → enters glycolysis at step 2 > **Clinical Correlation — Classic Galactosemia (GALT Deficiency):** > - **Autosomal recessive** deficiency of **galactose-1-phosphate uridylyltransferase** > - Galactose-1-phosphate accumulates in **liver, brain, kidney, lens** > - Galactose is also reduced to **galactitol** (by aldose reductase) → accumulates in lens → osmotic swelling → **cataracts** > - **Symptoms:** Neonatal jaundice, hepatomegaly, liver failure, **E. coli sepsis**, intellectual disability, cataracts, renal tubular dysfunction > - **Newborn screening** available (Beutler test — measures GALT activity; or measures total galactose) > - **Treatment:** Lifelong **galactose-free diet** (avoid milk and dairy) > - Despite treatment, many patients develop long-term complications (ovarian failure, speech/learning difficulties) — possibly due to endogenous galactose production > **Clinical Correlation — Galactokinase Deficiency:** > - Milder form; primarily causes **cataracts** (galactitol accumulation in lens) > - No liver or brain disease > - Treatment: galactose-restricted diet ### C. Mannose: 1. Mannose → **Mannose-6-phosphate** (Hexokinase) 2. Mannose-6-phosphate → **Fructose-6-phosphate** (Phosphomannose isomerase) 3. Enters glycolysis at step 3 > **Clinical Correlation — Congenital Disorders of Glycosylation (CDG):** > Phosphomannose isomerase deficiency causes **CDG type Ib** — one of the few treatable CDGs (treated with oral mannose supplementation). --- ## 13. THE THREE IRREVERSIBLE STEPS AND REGULATION SUMMARY The three irreversible reactions are the regulatory checkpoints: ### Step 1: Hexokinase/Glucokinase - **Regulatory significance:** Controls glucose entry into the cell's metabolic pathways - **Regulation:** Product inhibition by G6P (hexokinase only); GKRP regulates glucokinase - **Gluconeogenesis bypass:** **Glucose-6-phosphatase** (only in liver, kidney, intestine — NOT in muscle/brain) ### Step 3: PFK-1 ⭐ (RATE-LIMITING STEP) - **Regulatory significance:** The committed step of glycolysis; THE major control point - **Regulation:** Most extensively regulated enzyme (ATP, citrate, H⁺ inhibit; AMP, F2,6BP, Pᵢ activate) - **Gluconeogenesis bypass:** **Fructose-1,6-bisphosphatase (FBPase-1)** ### Step 10: Pyruvate Kinase - **Regulatory significance:** Controls the exit of glycolysis and carbon flow to pyruvate - **Regulation:** Allosteric (F1,6BP activates; ATP, alanine inhibit) + covalent modification (PK-L phosphorylated/inactivated by glucagon-PKA) - **Gluconeogenesis bypass:** **Pyruvate carboxylase** + **PEP carboxykinase (PEPCK)** (two enzymes needed to reverse this one step) --- ## 14. HORMONAL REGULATION OF GLYCOLYSIS ### Insulin (Fed State — Promotes Glycolysis): 1. **Increases glucose uptake:** Stimulates **GLUT4** translocation to muscle/adipose cell membranes 2. **Induces glucokinase** gene expression (liver) 3. **Activates PFK-2** (via phosphatase activation → dephosphorylation of bifunctional enzyme → increases F2,6BP → activates PFK-1) 4. **Activates pyruvate kinase-L** (dephosphorylation) 5. **Induces transcription** of glycolytic enzyme genes (GK, PFK-1, PK-L) via **SREBP-1c** and **ChREBP** transcription factors 6. Activates **pyruvate dehydrogenase** (indirectly) ### Glucagon (Fasting State — Inhibits Hepatic Glycolysis): 1. **cAMP → PKA pathway:** - Phosphorylates PFK-2/FBPase-2 → activates FBPase-2 → decreases F2,6BP → **inhibits PFK-1** - Phosphorylates PK-L → **inactivates PK-L** 2. **Represses transcription** of glycolytic enzyme genes 3. **Promotes gluconeogenesis** (opposite effects) 4. **Important:** Glucagon acts primarily on the **LIVER**, NOT on muscle (muscle lacks glucagon receptors in significant amounts) ### Epinephrine/Adrenaline: - In **muscle:** Promotes glycolysis via **β-adrenergic receptor** → cAMP → activates glycogen phosphorylase (glycogenolysis → more G6P) and enhances glucose uptake - In **liver:** Can act like glucagon (α₁ and β₂ receptors) → increases gluconeogenesis, glycogenolysis --- ## 15. PASTEUR EFFECT **Definition:** The **inhibition of glycolysis by oxygen** (aerobic conditions slow down glycolysis). **Mechanism:** - In the presence of O₂, mitochondria oxidize NADH efficiently → produces more ATP via oxidative phosphorylation - High ATP inhibits PFK-1 → slows glycolysis - Citrate levels increase (TCA cycle active) → citrate inhibits PFK-1 - Less glucose is consumed per unit of ATP produced (because oxidative phosphorylation is much more efficient: 30-32 ATP/glucose vs. 2 ATP/glucose from glycolysis alone) **Quantitatively:** Aerobic conditions reduce glucose consumption by ~18-fold compared to anaerobic conditions (because 30-32 ÷ 2 ≈ 15-16 times more efficient) **Exception:** The Pasteur effect does NOT occur in: - **Cancer cells** (Warburg effect — see below) - **RBCs** (no mitochondria) --- ## 16. WARBURG EFFECT (AEROBIC GLYCOLYSIS IN CANCER) **Definition:** Cancer cells preferentially utilize **glycolysis even in the presence of adequate oxygen** ("aerobic glycolysis"). Described by Otto Warburg (Nobel Prize 1931). **Features:** - Cancer cells consume glucose at rates **10–100 times higher** than normal cells - Produce large amounts of **lactate** even with ample O₂ - This seems paradoxically inefficient (2 ATP vs. 30-32 ATP per glucose) **Why do cancer cells do this?** 1. **Biosynthetic advantage:** Glycolytic intermediates are diverted to anabolic pathways: - G6P → pentose phosphate pathway → ribose-5-phosphate (nucleotides) + NADPH (lipid synthesis, antioxidant defense) - 3-PG → serine → glycine, one-carbon metabolism - DHAP → glycerol-3-phosphate → lipid synthesis - Pyruvate → alanine, oxaloacetate (via PC) 2. **Speed:** Glycolysis generates ATP **faster** (even though less efficiently) — advantageous when glucose is abundant 3. **Immune evasion:** Lactate acidifies the tumor microenvironment → suppresses immune cells (T cells, NK cells) 4. **PKM2 dimer** form channels intermediates to biosynthesis 5. **Genetic basis:** Oncogenes (Myc, Ras, Akt/PI3K, HIF-1α) upregulate glycolytic enzymes and glucose transporters (GLUT1, GLUT3) > **Clinical Application — PET Scan (¹⁸F-FDG PET/CT):** > - **Positron Emission Tomography** uses **¹⁸F-fluorodeoxyglucose (FDG)** — a glucose analog > - FDG is taken up by cells via GLUT transporters and phosphorylated by hexokinase to FDG-6-phosphate > - FDG-6-phosphate **CANNOT be further metabolized** (no -OH at C-2) and is **trapped** in the cell > - Cancer cells take up more FDG due to the Warburg effect → appear as **"hot spots"** on PET scan > - Used for **cancer staging, detection of metastases, monitoring treatment response** > - Also used in: epilepsy (seizure focus shows increased uptake during seizure), cardiac viability studies (viable but hibernating myocardium takes up FDG), infections/inflammation > **Clinical Correlation — Targeting the Warburg Effect (Cancer Therapy):** > Several approaches are under investigation: > 1. **2-Deoxyglucose (2-DG):** Glucose analog phosphorylated by hexokinase to 2-DG-6-P, which inhibits hexokinase and PGI → blocks glycolysis. Under clinical trials. > 2. **Dichloroacetate (DCA):** Inhibits pyruvate dehydrogenase kinase → activates PDH → pushes pyruvate into mitochondria instead of lactate → partially reverses Warburg effect > 3. **PFKFB3 inhibitors:** Lower F2,6BP → reduce PFK-1 activity > 4. **PKM2 activators:** Force PKM2 into active tetramer → reduce biosynthetic diversion > 5. **MCT (monocarboxylate transporter) inhibitors:** Block lactate export → intracellular acidification → cell death > 6. **HIF-1α inhibitors** > 7. **Metformin/Phenformin:** Inhibit Complex I → disrupt cancer metabolism (epidemiological data suggest diabetics on metformin have lower cancer incidence) --- ## 17. CRABTREE EFFECT **Definition:** The **inhibition of cellular respiration (oxidative phosphorylation) by high glucose concentrations** — the reverse of the Pasteur effect. - Observed in tumor cells and rapidly proliferating cells - High glucose → rapid glycolysis → produces large amounts of **cytoplasmic ATP and NADH** → suppresses mitochondrial respiration - Mechanism: Competition for ADP and Pᵢ between glycolysis and oxidative phosphorylation; also, glycolytic enzymes may sequester ADP --- ## 18. GLYCOLYSIS IN SPECIFIC TISSUES ### A. Erythrocytes (RBCs): - **No mitochondria** → glycolysis is the **ONLY** source of ATP - No TCA cycle, no ETC, no oxidative phosphorylation - Produce **2 ATP and 2 lactate** per glucose (always anaerobic glycolysis) - **2,3-BPG pathway** (Rapoport-Luebering shunt) is unique and essential for oxygen transport regulation - **HMP shunt** in RBCs produces NADPH for glutathione reduction → protection against oxidative damage - Glucose enters via **GLUT1** (insulin-independent) ### B. Brain: - High glucose demand (~120 g/day; ~20% of body's glucose consumption despite being only 2% of body weight) - Glucose enters via **GLUT1** (blood-brain barrier) and **GLUT3** (neurons) — both insulin-independent - Under normal conditions: glucose → pyruvate → acetyl-CoA → TCA → ETC (aerobic) - During starvation (prolonged): can adapt to use **ketone bodies** (acetoacetate, β-hydroxybutyrate) for up to 60-70% of energy needs - **Cannot use fatty acids** for energy (fatty acids cannot cross blood-brain barrier efficiently) > **Clinical Correlation — Hypoglycemia and Brain:** > Brain is exquisitely sensitive to hypoglycemia because: > - Cannot store significant glycogen > - Cannot oxidize fatty acids > - Depends on continuous glucose supply from blood > - Symptoms progress from **autonomic** (sweating, tremor, tachycardia — at glucose ~55-65 mg/dL) to **neuroglycopenic** (confusion, seizures, coma — at glucose < 40-50 mg/dL) > - Prolonged severe hypoglycemia causes **irreversible brain damage** and death ### C. Skeletal Muscle: - At rest: primarily uses **fatty acids** (aerobic metabolism) - During moderate exercise: uses glucose (aerobic glycolysis → TCA → ETC) - During intense/sprint exercise: blood supply cannot meet O₂ demand → **anaerobic glycolysis** → lactate production (causes muscle fatigue/soreness partially) - Has both **fast-twitch (type II) fibers** (glycolytic, more lactate production) and **slow-twitch (type I) fibers** (oxidative, more mitochondria) - Glucose enters via **GLUT4** (insulin-dependent; also translocated by exercise via AMPK) ### D. Liver: - Major role in glucose homeostasis - **Fed state:** Glycolysis active → converts excess glucose to pyruvate → acetyl-CoA → fatty acids (lipogenesis) or to glycogen - **Fasting state:** Glycolysis suppressed; gluconeogenesis and glycogenolysis produce glucose for export - Has **glucokinase** (not hexokinase) and **GLUT2** (bidirectional, high-capacity, insulin-independent transporter) - Has **glucose-6-phosphatase** → can release free glucose into blood (muscle CANNOT do this) ### E. Adipose Tissue: - Glycolysis provides **glycerol-3-phosphate** (from DHAP via glycerol-3-phosphate dehydrogenase) for **triglyceride synthesis** (esterification of fatty acids) - **Adipose tissue cannot significantly phosphorylate free glycerol** (low glycerol kinase activity) → must generate glycerol-3-phosphate from glycolysis - GLUT4 (insulin-dependent) ### F. Kidney: - Renal cortex: primarily oxidative (high mitochondria) - Renal medulla: relatively hypoxic → depends significantly on **anaerobic glycolysis** - Kidney is a significant site of **gluconeogenesis** (especially during prolonged fasting/starvation — contributes up to 40% of glucose production) --- ## 19. GLUCOSE TRANSPORTERS (GLUT/SLC2A FAMILY) | Transporter | Tissue | Km | Key Features | |---|---|---|---| | **GLUT1** | RBCs, brain (BBB), most tissues | ~1 mM (low Km = high affinity) | Basal glucose uptake; insulin-**independent** | | **GLUT2** | Liver, pancreatic β-cells, kidney, small intestine | ~15-20 mM (high Km = low affinity) | Bidirectional; acts as glucose "sensor" in β-cells; insulin-**independent** | | **GLUT3** | Neurons | ~1.4 mM (very low Km) | Highest affinity of all GLUTs; ensures neurons get glucose even at low levels; insulin-**independent** | | **GLUT4** | Skeletal muscle, cardiac muscle, adipose | ~5 mM | **Insulin-dependent** — stored in intracellular vesicles; insulin triggers translocation to cell surface; also stimulated by exercise (AMPK pathway) | | **GLUT5** | Small intestine (apical), spermatozoa | — | **Fructose** transporter (NOT glucose); facilitates dietary fructose absorption | | **GLUT7** | Liver ER membrane | — | Transports G6P into ER for glucose-6-phosphatase | | **SGLT1** | Small intestine (apical), kidney (S3) | — | **Sodium-dependent** glucose cotransporter; active transport; secondary active transport using Na⁺ gradient | | **SGLT2** | Kidney proximal tubule (S1/S2) | — | Reabsorbs ~90% of filtered glucose; target of **SGLT2 inhibitors** | > **Clinical Correlation — SGLT2 Inhibitors (Gliflozins):** > - **Empagliflozin, Dapagliflozin, Canagliflozin** — drugs for type 2 diabetes > - Block glucose reabsorption in kidney → **glycosuria** (glucose excretion in urine) → lowers blood glucose > - **Additional benefits:** Reduce cardiovascular mortality, slow progression of heart failure and chronic kidney disease (even in non-diabetics) > - **Side effects:** Urinary tract infections, genital yeast infections (glycosuria provides substrate for microbes), diabetic ketoacidosis (euglycemic DKA — rare but serious), Fournier's gangrene (rare) > **Clinical Correlation — GLUT1 Deficiency Syndrome:** > - Mutations in GLUT1 → impaired glucose transport across blood-brain barrier > - Low **CSF glucose** (CSF:blood glucose ratio < 0.4) with normal blood glucose > - Causes: Seizures, microcephaly, intellectual disability, movement disorders (dystonia, ataxia) > - Treatment: **Ketogenic diet** (provides ketone bodies as alternative brain fuel, bypassing the glucose transport defect) > **Clinical Correlation — Fanconi-Bickel Syndrome (GLUT2 Deficiency):** > - Mutations in GLUT2 → impaired glucose/galactose transport in liver, kidney, intestine > - Features: Hepatomegaly (glycogen storage), fasting hypoglycemia, postprandial hyperglycemia, renal tubular dysfunction (glucosuria, phosphaturia, aminoaciduria — Fanconi syndrome), rickets > - Also classified as **Glycogen Storage Disease Type XI** --- ## 20. INHIBITORS OF GLYCOLYSIS (SUMMARY) | Inhibitor | Target | Mechanism | |---|---|---| | **2-Deoxyglucose (2-DG)** | Hexokinase/PGI | Phosphorylated to 2-DG-6-P; competitive inhibitor of PGI; traps phosphate | | **Glucosamine** | Hexokinase | Competitive inhibitor | | **Iodoacetate/Iodoacetamide** | GAPDH | Alkylates Cys-149; irreversible inhibitor | | **Arsenate** | GAPDH (step 6) | Substitutes for Pᵢ → arsenolysis → bypasses ATP production in step 7 | | **Fluoride (NaF)** | Enolase | Forms Mg-fluorophosphate complex at active site | | **Oxalate** | Enolase | Chelates Mg²⁺ | | **High [ATP]** | PFK-1, PK | Allosteric inhibition | | **Citrate** | PFK-1 | Allosteric inhibition | | **Mercury, heavy metals** | Multiple (SH enzymes) | React with sulfhydryl groups | > **Clinical Correlation — Oxalate Poisoning:** > Oxalate (from ethylene glycol metabolism or dietary sources) inhibits several enzymes including enolase. **Ethylene glycol** (antifreeze) is metabolized to glycolaldehyde → glycolate → glyoxylate → **oxalate** by alcohol dehydrogenase and aldehyde dehydrogenase. Oxalate precipitates with calcium → **calcium oxalate crystals** in renal tubules → acute kidney injury. Treatment: **Fomepizole** (4-methylpyrazole — inhibits alcohol dehydrogenase) or ethanol (competitive substrate), plus hemodialysis. --- ## 21. GLYCOLYSIS AND THE PENTOSE PHOSPHATE PATHWAY (HMP SHUNT) — INTERCONNECTION - **Glucose-6-phosphate** is the branch point between glycolysis and the HMP shunt - Under oxidative stress or when NADPH/nucleotide synthesis is needed → G6P is diverted to HMP shunt - The non-oxidative phase of HMP shunt can feed back into glycolysis via **F6P** and **G3P** > **Clinical Correlation — G6PD Deficiency:** > **Glucose-6-phosphate dehydrogenase (G6PD)** deficiency (the first enzyme of the HMP shunt) is the **most common enzyme deficiency worldwide** (~400 million affected). > - **X-linked recessive** (males predominantly affected; females can be affected if homozygous or due to extreme lyonization) > - Decreased NADPH → decreased reduced glutathione (GSH) → RBCs vulnerable to **oxidative stress** → **hemolytic anemia** triggered by: > - Drugs: Primaquine, sulfonamides, dapsone, nitrofurantoin, rasburicase > - Foods: **Fava beans** (favism) — contain divicine and isouramil > - Infections (most common trigger) > - Mothballs (naphthalene) > - Diabetic ketoacidosis > - **Blood smear:** **Heinz bodies** (denatured hemoglobin precipitates — seen with supravital staining) and **bite cells/blister cells** (where Heinz bodies are removed by splenic macrophages) > - While not directly a glycolytic defect, it affects how G6P is channeled and is relevant to carbohydrate metabolism --- ## 22. GLUCONEOGENESIS — BRIEF COMPARISON WITH GLYCOLYSIS Gluconeogenesis is essentially the **reverse of glycolysis** but uses **four different enzymes** to bypass the three irreversible steps: | Glycolytic Enzyme (Irreversible) | Gluconeogenic Bypass Enzyme | |---|---| | Hexokinase/Glucokinase | **Glucose-6-phosphatase** (ER membrane) | | PFK-1 | **Fructose-1,6-bisphosphatase** (FBPase-1) | | Pyruvate Kinase | **Pyruvate carboxylase** (mitochondria, requires biotin) + **PEP carboxykinase (PEPCK)** | - The seven reversible steps of glycolysis are shared with gluconeogenesis (catalyzed by the same enzymes running in reverse) - Glycolysis and gluconeogenesis are **reciprocally regulated** — when one is active, the other is suppressed. The key regulator is **fructose-2,6-bisphosphate** (activates PFK-1/glycolysis; inhibits FBPase-1/gluconeogenesis) --- ## 23. GLYCOLYTIC ENZYME DEFICIENCIES — COMPREHENSIVE CLINICAL SUMMARY All glycolytic enzyme deficiencies that affect RBCs cause **hereditary non-spherocytic hemolytic anemia** (because RBCs depend entirely on glycolysis). The severity varies: | Enzyme Deficiency | Inheritance | Key Features | |---|---|---| | Hexokinase | AR | Hemolytic anemia; ↓2,3-BPG → left shift | | Phosphoglucose isomerase | AR | 2nd most common; hemolytic anemia | | PFK-1 (M subunit) | AR | **Tarui disease (GSD VII)**; exercise intolerance, hemolytic anemia, hyperuricemia | | Aldolase A | AR | Hemolytic anemia, myopathy, rhabdomyolysis; very rare | | Triose phosphate isomerase | AR | **Most severe**; hemolytic anemia, progressive neurodegeneration, cardiomyopathy; early death | | GAPDH | — | Extremely rare; not well characterized | | Phosphoglycerate kinase | **X-linked** | Hemolytic anemia, myopathy, intellectual disability | | Phosphoglycerate mutase | AR | Myopathy, exercise intolerance, rhabdomyolysis | | Enolase (β subunit) | AR | Myopathy; extremely rare | | **Pyruvate kinase (PK-R)** | AR | **Most common** glycolytic enzymopathy; hemolytic anemia; ↑2,3-BPG → right shift (compensatory); echinocytes on smear | --- ## 24. THERMODYNAMICS OF GLYCOLYSIS | Step | ΔG°' (kJ/mol) | ΔG in cell (kJ/mol) | Nature | |---|---|---|---| | 1 | −16.7 | −33.4 | **Irreversible** | | 2 | +1.7 | −2.5 | Near-equilibrium | | 3 | −14.2 | −22.2 | **Irreversible** | | 4 | +23.8 | −1.3 | Near-equilibrium (driven by product removal) | | 5 | +7.5 | +2.5 | Near-equilibrium | | 6 | +6.3 | −1.7 | Near-equilibrium | | 7 | −18.5 | +1.3 | Near-equilibrium | | 8 | +4.4 | +0.8 | Near-equilibrium | | 9 | +7.5 | +0.3 | Near-equilibrium | | 10 | −31.4 | −16.7 | **Irreversible** | **Key insight:** The standard free energy change (ΔG°') and the actual free energy change in the cell (ΔG) can be very different because ΔG depends on actual substrate and product concentrations. Steps 4, 7, and 9 have large positive ΔG°' values but are near-equilibrium in cells because of concentration effects. --- ## 25. EVOLUTIONARY SIGNIFICANCE 1. **Glycolysis evolved very early** — before O₂ appeared in the atmosphere (~3.5 billion years ago) 2. The pathway is present in **virtually all organisms** — from archaea to humans 3. It reflects an **anaerobic origin** — does not require oxygen 4. The enzymes are **highly conserved** across species (e.g., TPI from humans and bacteria share >50% sequence identity) 5. The cytoplasmic location is consistent with its evolution **before the endosymbiotic origin of mitochondria** --- ## 26. SUBSTRATE-LEVEL PHOSPHORYLATION vs. OXIDATIVE PHOSPHORYLATION | Feature | Substrate-Level Phosphorylation | Oxidative Phosphorylation | |---|---|---| | Location | Cytoplasm (glycolysis) and mitochondrial matrix (TCA) | Inner mitochondrial membrane | | Oxygen required | **No** | **Yes** | | Mechanism | Direct transfer of phosphoryl group from high-energy substrate to ADP | Chemiosmotic coupling — proton gradient drives ATP synthase | | Examples | Steps 7 and 10 of glycolysis; succinyl-CoA synthetase (TCA) | Complex V (ATP synthase) | | ATP yield | Small (2 per glucose from glycolysis) | Large (~26-28 per glucose) | | Speed | Fast | Slower | | Coupled to | Specific enzymatic reactions | Electron transport chain | --- ## 27. SUMMARY: NET REACTION AND ENERGY BALANCE ### Overall Equation (Aerobic): ``` Glucose + 2 NAD⁺ + 2 ADP + 2 Pᵢ → 2 Pyruvate + 2 NADH + 2 H⁺ + 2 ATP + 2 H₂O ``` ### Overall Equation (Anaerobic — Homolactic Fermentation): ``` Glucose + 2 ADP + 2 Pᵢ → 2 Lactate + 2 ATP + 2 H₂O ``` (NAD⁺ is regenerated by LDH, so net NAD⁺ change = 0) ### Overall Equation (Anaerobic — Alcoholic Fermentation): ``` Glucose + 2 ADP + 2 Pᵢ → 2 Ethanol + 2 CO₂ + 2 ATP + 2 H₂O ``` --- ## 28. HIGH-YIELD CLINICAL CORRELATIONS — ADDITIONAL TOPICS ### A. Von Gierke Disease (GSD Type I — Glucose-6-Phosphatase Deficiency): - Cannot convert G6P → glucose in liver → severe **fasting hypoglycemia** - G6P accumulates → drives glycolysis → **increased lactate** (lactic acidosis) - G6P also drives HMP shunt and glycogen synthesis → **hepatomegaly** (massive glycogen accumulation), **hyperlipidemia** (↑ acetyl-CoA → lipogenesis), **hyperuricemia** (HMP → ↑ ribose-5-P → ↑ purine synthesis → ↑ uric acid) ### B. Thiamine (Vitamin B₁) Deficiency: - Thiamine is not directly required for glycolysis, but is essential for **pyruvate dehydrogenase** (which processes glycolytic output) - Deficiency → pyruvate cannot enter TCA → accumulates → converted to **lactate** → lactic acidosis - Clinical: **Beriberi** (wet beriberi = cardiac; dry beriberi = neurological), **Wernicke-Korsakoff syndrome** (alcoholics) - Pyruvate and lactate levels elevated; pyruvate/lactate ratio may be altered ### C. Diabetes Mellitus and Glycolysis: - **Type 1 DM:** Insulin deficiency → ↓GLUT4 translocation → ↓glucose uptake by muscle/adipose → hyperglycemia, but cells are glucose-starved - **Type 2 DM:** Insulin resistance → similar effects - Chronic hyperglycemia → increased flux through **polyol pathway** (aldose reductase converts glucose → sorbitol → fructose) in insulin-independent tissues (lens, retina, kidney, peripheral nerves, Schwann cells) → osmotic damage → **diabetic complications** (cataracts, retinopathy, nephropathy, neuropathy) - Increased DHAP/G3P → methylglyoxal → AGEs → vascular damage ### D. Hemolytic Anemias of the Newborn: - Newborns have lower levels of several glycolytic enzymes and 2,3-BPG - **Neonatal jaundice** can be exacerbated by RBC enzyme deficiencies (G6PD, PK) - Kernicterus risk if severe ### E. Pyruvate Dehydrogenase (PDH) Deficiency: - Not a glycolytic enzyme per se, but directly downstream - Pyruvate cannot be converted to acetyl-CoA → ↑ pyruvate → ↑ **lactate** → **congenital lactic acidosis** - Most common cause of congenital lactic acidosis - **X-linked** (PDH E1α subunit on X chromosome) - Features: Lactic acidosis, intellectual disability, seizures, hypotonia; often fatal in infancy - Treatment: **Ketogenic diet** (provides acetyl-CoA from β-oxidation, bypassing PDH) + **thiamine** (cofactor for PDH — some mutations are thiamine-responsive) + **dichloroacetate** (activates PDH by inhibiting PDH kinase) --- ## 29. MNEMONICS ### For the 10 enzymes in order: **"Hungry Peter Pan And The Growling, Pink Panther Eat Pie"** 1. **H**exokinase 2. **P**hosphoglucose isomerase 3. **P**hosphofructokinase-1 4. **A**ldolase 5. **T**riose phosphate isomerase 6. **G**lyceraldehyde-3-phosphate dehydrogenase 7. **P**hosphoglycerate kinase 8. **P**hosphoglycerate mutase 9. **E**nolase 10. **P**yruvate kinase ### For the 10 intermediates: **"Good Girls Finish First, Don't Give Boys Beverages Before Parties with Pep and Pie"** 1. **G**lucose 2. **G**lucose-6-phosphate 3. **F**ructose-6-phosphate 4. **F**ructose-1,6-bisphosphate 5. **D**HAP / **G**3P 6. **1,3-B**isphosphoglycerate 7. **3-P**hosphoglycerate 8. **2-P**hosphoglycerate 9. **P**EP (**Pep**) 10. **P**yruvate (**Pie**) ### Irreversible steps (regulatory enzymes): **"HaPPy PiKnickers"** — **H**exokinase, **P**FK-1, **P**yruvate **K**inase --- ## 30. FINAL COMPREHENSIVE SUMMARY TABLE | Parameter | Detail | |---|---| | Pathway | Embden-Meyerhof-Parnas Pathway | | Location | Cytoplasm (cytosol) | | Substrate | 1 Glucose (6C) | | Products | 2 Pyruvate (3C each) | | O₂ required | No (anaerobic) | | ATP consumed | 2 (steps 1, 3) | | ATP produced | 4 (steps 7×2, 10×2) | | **Net ATP** | **2** | | NADH produced | 2 (step 6 ×2) | | Number of steps | 10 | | Irreversible steps | 3 (steps 1, 3, 10) | | Rate-limiting enzyme | PFK-1 (step 3) | | Most potent activator of PFK-1 | Fructose-2,6-bisphosphate | | Key hormonal regulation | Insulin (promotes), Glucagon (inhibits in liver) | | Substrate-level phosphorylation steps | Steps 7 and 10 | | Unique RBC pathway | Rapoport-Luebering shunt (2,3-BPG) | | Most common enzyme deficiency | Pyruvate kinase (PK-R) | | Most severe enzyme deficiency | Triose phosphate isomerase | | Cancer connection | Warburg effect; PKM2; PET-FDG scanning | | Blood collection tube additive | NaF (inhibits enolase) | --- This comprehensive guide covers virtually every aspect of glycolysis — from molecular mechanisms, enzyme kinetics, and regulation to clinical correlations spanning metabolic diseases, cancer biology, hematology, diabetes, toxicology, and pharmacology. Each step has been explained with its enzyme, substrates, products, mechanism, energetics, and relevant clinical applications. Rewrite this whole chat as it is